Trial Profile
Impact of appropriately managed Proton Pump Inhibitor use on the efficacy of Ledipasvir/Sofosbuvi +/- Ribavirin for the treatment of HCV infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Proton pump inhibitors; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 25 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017